Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Treatment of Port Wine Stains With 595-Nm Pulsed Dye Laser in 27 Pediatric Patients: A Prospective Study in the Iranian Population Publisher Pubmed



Sadeghinia A1 ; Moghaddas S1 ; Tavakolpour S1 ; Teimourpour A2 ; Danespazhooh M1 ; Mahmoudi H1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Cosmetic and Laser Therapy Published:2019


Abstract

Port wine stain (PWS) is a congenital vascular malformation, which is visible at the birth as the red patches, mostly on the face and neck. Previous studies have shown good efficacy and safety of 595-nm pulsed dye laser (PDL). Here, we have conducted a prospective study to assess the efficacy and safety profile of pediatrics with PWS, treated with 595-nm PDL. Twenty-seven patients (10 males and 17 females) with the mean age of 5.7 ± 2.8 (range 1–13) years old were included in the study. Following 6.2 (range 4–10) sessions of treatment, 70.74 ± 18.5% of improvement was detected three months after the final session. Fourteen (51.8%) patients achieved a higher than 75% of improvement; nine (33.4%) patients experienced 50%-75% improvement; four (14.8%) patients experienced a less than 50% improvement. V1 involvement and a marked improvement within the first five sessions found to be good prognostic factors. Regarding age, sex, skin type, color and size of the PWS, no significant association with therapeutic response were detected. Blister and crust, atrophic macules, and hyperpigmentation were noted in six (22.2%), one (3.7%), and one (3.7%), respectively. In conclusion, 595-nm PDL looks an effective and relatively safe therapeutic approach in the treatment of Iranian pediatric PWS patients. © 2019, © 2019 Taylor & Francis Group, LLC.